A 12week, double-blind, randomized, placebo-controlled clinical trial for the evaluation of the efficacy and safety of concentrated powder of Oenanthe javanica on improving liver function.
- Conditions
- Diseases of the digestive system
- Registration Number
- KCT0000820
- Lead Sponsor
- MSC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 76
1. Between more than the normal value of normal AST, ALT, and GGT and less than 3 times of normal AST, ALT, and GGT level
(AST;39-114, ALT;44-129, and GGT:76-225 at screening period)
1. patients who are taking treatment due to alcohol abuse, alcohol-related disease, heart disease and CNS disease
2. liver cirrhosis or hepatoma on sonography
3. viral hepatitis
4. HBs Ag(+), or HCV Ab(+)
5. sujects who took medication of liver mediated metabolism such ad INH, valproic acid, tetracycline, allopurinol, ibuprofen, phenytoin phenelzin, sertraline, naproxen, diclofenac, and any drug affecting liver toxicity within 4 weeks before enroll.
6. subjects who are taking steroid or sex hormone within 4 weeks before enroll.
7. intractable hypertension(over 160/100mg) or DM with more than 180mg/dl of fasting glucose .
8. Newly taking antilipidemic drug of DM medication wihtin 3 months before enroll.
9. during pregnancy or plan of pregnancy
10. subjects who are registered on the other clinical research within 1 month before enroll.
11. subjects pressumed as not appropriate by researchers.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change of AST(GOT);Change of ALT(GPT);Change of and ?-GTP
- Secondary Outcome Measures
Name Time Method change of ratio of AST/ALT; change of MFS scores ; change of total cholesterol, LDL and HDL cholesterol